Real Time Search
CES A80 :
CES 120 :
Total Turn.

Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment

2023-12-06 01:01:00

HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 6, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced the successful completion of Cohort 1 in an ongoing Phase I clinical trial of STP122G, targeting Factor XI as a novel form of anticoagulation.

Cohort 1 is comprised of eight subjects who completed dosing and were followed over a period of 140 days. Safety data showed there were no dose-limiting toxicities or serious adverse events, so the study will proceed to the next dosing cohort. Sirnaomics plans to enroll up to five escalating dosing cohorts.

The phase I, multicenter, randomized, double-blind, sequential cohort study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single ascending dose of STP122G when administered subcutaneously to healthy participants. The safety and tolerability will be compared among five different doses of STP122G (25 mg, 50 mg, 100 mg, 200 mg, 400 mg) to select one for future studies. The study plans to recruit 40 total participants.

"STP122G is the first candidate to move through clinical trials as part of our GalAhead™ Factor XI RNAi therapeutic program," said Dr. Patrick Lu, Founder, Chairman of the Board, Executive Director, President and Chief Executive Officer of Sirnaomics. "By targeting Factor XI, STP122G may have applications across a broad range of conditions that would benefit from a novel form of anticoagulation therapy such as prevention of deep vein thrombosis, treatment of atrial fibrillation for stroke prevention, and treatment of pulmonary embolism. There is a very large market opportunity for novel, safe anticoagulants and the benefits of siRNA therapies in relation to method of administration and longer duration of action should fit very well in the conditions we are targeting. We look forward to continuing to examine the efficacy of STP122G into 2024."

"The completion of the first-in-human, dosing cohort of our GalNAc-based platform is encouraging," said Dr. Francois Lebel, M.D., Chief Medical Officer of Sirnaomics. "As expected, the safety profile was found to be acceptable by prespecified protocol criteria and is allowing us to escalate further. In the next two or three dose cohorts, we expect to highlight the pharmacodynamic properties of this novel molecule directed at a validated target. The observation period between cohorts is related to the anticipated sustained pharmacologic effect of STP122G, a desirable characteristic for an anticoagulant."

STP122G is a third-generation Factor XI inhibitor in cases where prior treatments have not completely prevented bleeding for patients with anticoagulant disorders. Factor XI is an enzyme produced predominantly by hepatocytes in the liver and it plays an important role in the body's blood clotting cascade. By inhibiting Factor XI, STP122G may have a better safety profile than current anticoagulant drugs. There are three types of Factor XI inhibitors currently on the market or in clinical trials: RNA-based, small molecule, and monoclonal antibody treatments. As an RNA-based treatment driven by Sirnaomics' GalAhead™ delivery system, STP122G targets the hepatocyte to inhibit the production of Factor XI, which could offer long-term efficacy and less risk of bleeding.

Additional information about this clinical trial is available at using the identifier: NCT05844293.

– End –

About STP122G

STP122G is Sirnaomics' leading GalAhead™ Factor XI RNAi drug candidate. Sirnaomics submitted a U.S. IND for STP122G in March 2023 and launched a Phase I clinical trial in April 2023 as part of the Group's Factor XI Program. This program is applicable across a broad range of disease indications such as an anticoagulation, prevention and treatment of stroke after atrial fibrillation, cancer after immunotherapy, and improving total knee replacement recovery. STP122G is the inaugural candidate utilizing Sirnaomics' proprietary GalNAc RNAi platform technology, GalAhead™.

About Sirnaomics (stock code: 2257)

Sirnaomics is an RNA therapeutics biopharmaceutical company that focuses on the discovery and development of innovative drugs for indications with unmet medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAhead™, Sirnaomics has established an enriched drug candidate pipeline. STP122G, which represents the first drug candidate utilizing the Company's GalAhead™ technology, is currently in Phase I development. The Company has also had multiple successes with oncology applications through its clinical programs for STP705 and STP707. With the establishment of the Group's manufacturing facility in China, Sirnaomics is undergoing a transition from a biotech company to a biopharma corporation. Learn more at: .


PR Newswire News

Lion Enhances OTC Stock Options Services Quality and Efficiency Powered by AI
Autohome Inc. Announces 2023 Q4 and Annual Earnings: New Business Drives Sustained Growth
U Power and Cornerstone Sign MoU to Explore the Application of New Energy Charging Equipment and EV Product Solutions in Hong Kong and Southeast Asia
Autohome Inc. Announces Unaudited Fourth Quarter and Full Year 2023 Financial Results
HKBN and TP-Link Debut One-stop "Priority Plus" Home Wi-Fi Solution
Baidu to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28, 2024
"Eddid ONE USA": New Stock Trading App Debuts in the UK, USA, and Canada, Unlocking US Stock Market Opportunities for Global Investors
Futu Clinches Multiple CME Accolades, Affirming Industry Leadership with a Commitment to Deliver Diverse and Flexible Portfolios for Global Investors
Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval
China Southern Airlines Company Limited Intends to Deregister and Terminate Its Reporting Obligations Under the U.S. Securities Exchange Act of 1934
Innovent Announces Retirement of CFO and Appointment of New CFO
CNOOC Limited Announces Suizhong 36-1/Luda 5-2 Oilfield Secondary Adjustment and Development Project Commences Production
XTransfer Named to the 2023 Deloitte China Technology Fast 50™ Awards Program as the Only Cross-border Payment Platform
13:57:00 Group celebrates Lunar New Year travel boom with 10-fold jump in bookings as visa policies ease
Tan Xuguang Leads Shandong Heavy Industry in Reflecting on 20 Years of Global Expansion at CEO Summit
A Million-Dollar Airdrop Event for Celebrating Live4Well's first 150,000 Users Downloads In the First Month of launching.
World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap
Weichai Group Advances Toward Becoming a Global Leader in Technological Innovation
Beauty Farm Issues Positive Profit Alert for 2023
DFS Makes History as Douyin Life Service's First Cross-Border Retail Partner, Revolutionizing Chinese Customers' International Luxury Travel Retail Shopping Experience
Back to Top